Giant MagnetoResistive (GMR) Sensors for Measuring Influenza Vaccine

用于测量流感疫苗的巨磁阻 (GMR) 传感器

• 批准号: 9753117
• 负责人: PAUL JOSEPH UTZ
• 金额: $ 100万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-10 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9753117
• 关键词: ATAC-seq; Aging; B cell repertoire; Big Data; Bioinformatics; Biological; Biological Assay; Biological Markers; Biological Process; Biology; Blood specimen; CEB1 Gene; Cell surface; Clinic; Clinical; Communicable Diseases; Complex; DNA; Data Set; Emerging Communicable Diseases; Enrollment; Evaluation; Event; Flow Cytometry; Foundations; Funding; Genes; Goals; Hepatitis B Antibodies; Human; IFI6 gene; Immune; Immunity; Immunologic Monitoring; Immunology; Infection; Infectious Agent; Influenza; Influenza vaccination; LY6E gene; Measurement; Measures; Messenger RNA; Microfluidics; National Institute of Allergy and Infectious Disease; Outcome; Pathway interactions; Patient-Focused Outcomes; Patients; Peptides; Plasma; Proteins; RNA; Recovery; Research; Sampling; Serum; Signal Transduction; System; Systems Biology; T-Lymphocyte; Technology; Testing; Time; Transcript; Translating; Translations; Vaccination; Vaccines; Validation; Viral Vaccines; Virus Diseases; assay development; base; biomarker panel; cohort; cytokine; flexibility; genetic signature; human subject; improved outcome; influenza virus vaccine; influenzavirus; multidisciplinary; new therapeutic target; pathogen; predicting response; predictive marker; predictive signature; priority pathogen; response; rural setting; seasonal influenza; sensor; transcriptome sequencing; vaccine response; vaccine trial

7. Project Summary/Abstract The goal of this application is to identify predictive markers for outcomes of natural infection and/or vaccination with influenza, markers that are perhaps applicable to other infectious agents defined in the RFA. We have assembled a multi-disciplinary team composed of relevant infectious disease experts, clinical experts with access to appropriate patient samples, and experts in assay development, qualification, and validation. We will take advantage of a newly discovered predictive signature from the Khatri lab; unique clinical cohorts developed by the Dekker and Davis groups; Stanford’s Human Immune Monitoring Center (HIMC) for analysis of blood samples using Fluidigm, FACS and CyTOF; and expertise in multiplexed assay development by the Wang and Utz labs. Although beyond the scope of our application, the biomarker signature and the assays developed herein can be used to study other infectious agents and vaccine strategies that will be funded under this RFA mechanism. Our three specific aims will focus on the validation, application and translation of this signature. Specific Aim 1 is to validate a panel of biomarkers for their ability to predict response to influenza vaccination and recovery from wild-type influenza virus infection. Specific Aim 2 will characterize biological pathways identified in Aim 1 using well-established and previously described patient cohorts, and to compare the existing biomarker datasets that are available. Finally, Specific Aim 3 will develop a rapid, multiplexed assay for measuring transcripts using Giant MagnetoResistive (GMR) Sensors, with a long term goal to build a sensor capable of measuring multiple transcripts within minutes at point-of-assay. Our studies will enhance our understanding of the important biological processes involved in response to influenza and other pathogens, and will provide a clinically accessible immune metric for rapid or even real-time evaluation of patients and vaccines.

7. 项目总结/摘要 该应用程序的目标是识别自然感染结果的预测标记和/或 流感疫苗接种，可能适用于定义的其他传染原的标记 我们在 RFA 组建了一支由相关传染病组成的多学科团队。 专家、能够获取适当患者样本的临床专家以及化验专家 我们将利用新发现的预测。 Khatri 实验室的签名；由 Dekker 和 Davis 小组开发的独特临床队列； 斯坦福大学人类免疫监测中心 (HIMC) 使用以下方法分析血液样本 Fluidigm、FACS 和 CyTOF；以及 Wang 和 尽管超出了我们的应用范围，但生物标志物特征和检测方法。 开发的文件可用于研究其他感染原和疫苗策略 我们的三个具体目标将集中在验证和应用上。 具体目标 1 是验证一组生物标志物的能力。 预测对流感疫苗接种的反应和野生型流感病毒感染的恢复。 具体目标 2 将使用成熟且可靠的方法来描述目标 1 中确定的生物途径的特征。 先前描述的患者队列，并比较现有的生物标志物数据集 最后，Specific Aim 3 将开发一种快速、多重检测方法来测量转录本。 使用巨磁阻 (GMR) 传感器，长期目标是构建能够 在检测点几分钟内测量多个转录本将增强我们的研究。 了解应对流感和其他疾病所涉及的重要生物过程 病原体，并将提供临床上可访问的免疫指标，用于快速甚至实时 对患者和疫苗的评估。